Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy
Harbin Medical University · Second Affiliated Hospital of Harbin Medical University · +1 more institution
Abstract
Metformin is a widely used antidiabetic drug for type 2 diabetes that can play a cardioprotective role through multiple pathways. It is a recognized agonist of AMP-activated protein kinase (AMPK) that blocks mitochondrial complex I. The NLRP3 inflammasome has been demonstrated to be activated in diabetic cardiomyopathy (DCM). However, the role of metformin in regulating the NLRP3 signaling pathway in DCM remains unclear. It has been reported that AMPK can inhibit NLRP3 by activating autophagy. The aim of this study was to investigate whether metformin can inhibit the NLRP3 inflammasome by activating the AMPK/mTOR pathway in DCM. In this study, streptozotocin-induced C57BL/6 mice and high glucose-treated…
Citation impact
- FWCI
- 15.46
- Percentile
- 100%
- References
- 55
Authors
11- FYFan Yang
Harbin Medical University, Second Affiliated Hospital of Harbin Medical University
- YQYing� Qin
Heilongjiang Academy of Sciences
- YWYueqiu Wang
Harbin Medical University, Second Affiliated Hospital of Harbin Medical University
- SMSongyan Meng
Harbin Medical University, Second Affiliated Hospital of Harbin Medical University
- HXHuimin Xian
Harbin Medical University, Second Affiliated Hospital of Harbin Medical University
Topics & keywords
- Metformin
- AMPK
- Diabetic cardiomyopathy
- Autophagy
- Inflammasome
- PI3K/AKT/mTOR pathway
- Pharmacology
- Pyroptosis
- Good health and well-being